Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial

Lancet

Volumn 357, Issue 9266, 2001, Pages 1385-1390

  Dargie, H J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035810547     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04560-8     Document Type: Article

References (17)

1. Norwegian Multicentre Group. Timolol induced reductionin mortality and reinfarction in patients surviving acutemyocardial infarction. N Engl J Med 1981; 304: 801-07.
2. β-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982; 247: 1707-14.
3. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.
4. Packer M., Bristow M., Cohn J., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
5. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
6. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-07.
7. The Australia-New Zealand Carvedilol Study Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
8. Spargias K.S., Hall A.S., Greenwood D.C., et al. β Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart. 81:1999;25-32.
9. Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 318:1999;1730-1738.
10. Vantrimpont P., Rouleau J.C., Wun C.C., for the SAVE investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997; 29: 229-36.
11. Pfeffer M.A., Braunwald E., Moye L.A., et al. on behalf theSAVE investigators. Effect of captopril on mortalityand morbididty in patients with left ventricular dysfunctionafter myocardial infarction. Results of the Survival andVentricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28.
13. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
14. Krumholz H.M., Radford M.S., Wang Y., et al. National use and effectiveness of beta blockers for the treatment of elderly patients after acute myocardial infarction. JAMA. 280:1998;623-629.
15. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta blockade on mortality among high risk and low risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497.
16. Dargie H.J., on behalf of the CAPRICORN Steering Committee. Design and methodology of the CAPRICORN trial: a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Failure 2000; 2: 325-32.
17. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G. Long-term ACE-inhibitor therapy in patients with heartfailure or left-ventricular dysfunction: a systematic overviewof data from individual patients. Lancet. 355:2000;1575-1581.